Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This report describes two patients with atopic dermatitis receiving dupilumab, where one experienced healing of alopecia areata and the other developed it, illustrating the drug's varied effects.

This study found that JAM-A modification in mouse wound models significantly promoted wound healing and fibroblast proliferation, potentially linked to increased levels of growth factors bFGF and EGF.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

Dental professionals should ensure safety in facial aesthetics by being properly trained and registered.

This article reviews techniques for rejuvenating the lower face, neck, and jawline using newer cosmetic interventions and reports no new clinical results.

This journal overview describes the Dermatologic Surgery journal's focus on cosmetic and reconstructive skin surgery and skin cancer but reports no new research findings.

This study evaluated eight JAK inhibitor regimens for alopecia areata and provided high-quality evidence on their comparative effectiveness, which can aid clinicians in decision-making and inform medical practice guidelines.

This study found that DALL-E 2 performed poorly in generating accurate images of most pediatric dermatological conditions, highlighting the need for more domain-specific and inclusive training data.

This study developed a method using ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MRM-IDA-EPI) for the rapid and sensitive detection of 13 JAK inhibitors in anti-alopecia cosmetics, showing excellent separation and accurate quantification with high recovery rates in tested matrices.

Tissue-engineered skin substitutes can model junctional epidermolysis bullosa and may help develop gene therapy.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

In this analysis, JAK inhibitors were found to provide clinically meaningful and durable hair regrowth in pediatric alopecia areata, outperforming traditional therapies with a manageable safety profile.

This archive describes the Bioline International platform, which hosted open access journals from developing countries but reports no new research findings.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

This journal overview highlights the expansive coverage of cosmetic and reconstructive skin surgery, but reports no new research findings.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.